MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Prevalence of Supine Hypertension in Alpha-Synucleinopathies: a Systematic Review and Meta-Analysis

V. Arca, PR. Lopes, FL. Westphal Filho, F. Mendes Filho, C. Falcão, J. Parmera (São Paulo, Brazil)

Meeting: 2025 International Congress

Keywords: Alpha-synuclein, Autonomic dysfunction, Parkinson’s

Category: Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)

Objective: We aimed to conduct a systematic review and meta-analysis to assess the prevalence of supine hypertension (SH) in α-synucleinopathies.

Background: Alpha-synucleinopathies, including Parkinson’s Disease (PD), Dementia with Lewy Bodies (DLB), Multiple System Atrophy (MSA), and Pure Autonomic Failure (PAF), are associated with autonomic dysfunctions such as orthostatic hypotension (OH) and supine hypertension. SH, characterized by elevated supine blood pressure, carries significant cardiovascular and cognitive risks, yet its prevalence in a-synucleinopathies remains inadequately defined.

Method: We systematically searched PubMed, Embase, and Web of Science databases for studies reporting SH prevalence in patients with α-synucleinopathies. A random-effects model estimated prevalence, stratified by disease type, study design, SH definition, OH presence, and disease duration. Sensitivity analyses were applied to explore sources of variability.

Results: Nineteen studies involving 4973 patients were included. The overall SH prevalence was 30.4% (95% CI: 26.4–34.7; I² = 87.6%). In PD, SH prevalence was 28.3% (95% CI: 24.0–32.9), with OH significantly increasing prevalence (33.9% vs. 21.3%, p = 0.0341). In MSA, SH prevalence was 31.1% (95% CI: 25.9–36.9; I² = 30.5%), with OH presence similarly associated with higher SH prevalence (46.5% vs. 19.8%, p = 0.0023). In DLB, the pooled SH prevalence was 48.7% (95% CI: 39.5–58.1; I² = 11.9%). For PAF, a single study reported a prevalence of 48.4% (95% CI: 35.7–61.2).

Conclusion: SH is highly prevalent across a-synucleinopathies, with variability by disease type and OH presence. Standardizing diagnostic criteria and investigating its clinical implications are essential to enhance management strategies.

To cite this abstract in AMA style:

V. Arca, PR. Lopes, FL. Westphal Filho, F. Mendes Filho, C. Falcão, J. Parmera. Prevalence of Supine Hypertension in Alpha-Synucleinopathies: a Systematic Review and Meta-Analysis [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/prevalence-of-supine-hypertension-in-alpha-synucleinopathies-a-systematic-review-and-meta-analysis/. Accessed November 20, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/prevalence-of-supine-hypertension-in-alpha-synucleinopathies-a-systematic-review-and-meta-analysis/

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley